首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2604604篇
  免费   215458篇
  国内免费   17236篇
耳鼻咽喉   37125篇
儿科学   77724篇
妇产科学   69360篇
基础医学   358784篇
口腔科学   72541篇
临床医学   242538篇
内科学   500865篇
皮肤病学   50937篇
神经病学   212431篇
特种医学   104405篇
外国民族医学   1002篇
外科学   388862篇
综合类   92566篇
一般理论   1044篇
预防医学   205770篇
眼科学   62482篇
药学   200640篇
  132篇
中国医学   15110篇
肿瘤学   142980篇
  2021年   21598篇
  2019年   26438篇
  2018年   29997篇
  2017年   24992篇
  2016年   25680篇
  2015年   31923篇
  2014年   45061篇
  2013年   61462篇
  2012年   84590篇
  2011年   89647篇
  2010年   53329篇
  2009年   49418篇
  2008年   80246篇
  2007年   84696篇
  2006年   85238篇
  2005年   83494篇
  2004年   77061篇
  2003年   73831篇
  2002年   72088篇
  2001年   116449篇
  2000年   120634篇
  1999年   102691篇
  1998年   29354篇
  1997年   27097篇
  1996年   26211篇
  1995年   26834篇
  1994年   25084篇
  1993年   22804篇
  1992年   80916篇
  1991年   77834篇
  1990年   74738篇
  1989年   71830篇
  1988年   66680篇
  1987年   65570篇
  1986年   61952篇
  1985年   58873篇
  1984年   44465篇
  1983年   37794篇
  1982年   22934篇
  1979年   41400篇
  1978年   29001篇
  1977年   24288篇
  1976年   22746篇
  1975年   23912篇
  1974年   29612篇
  1973年   28028篇
  1972年   26216篇
  1971年   24159篇
  1970年   22749篇
  1969年   21067篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%–80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year. For the past decade, doublet chemotherapy with gemcitabine and cisplatin has been considered the most effective first-line regimen, but results from the recent use of triplet regimens and even immunotherapy may shift the paradigm. More effective treatment strategies, including those that combine systemic therapy with locoregional therapies like radioembolization or hepatic artery infusion, have also been developed. Molecular therapies, including those that target fibroblast growth factor receptor and isocitrate dehydrogenase, have recently received US Food and Drug Administration approval for a defined role as second-line treatment for up to 40% of patients harboring these actionable genomic alterations, and whether they should be considered in the first-line setting is under investigation. Furthermore, as the oncology field seeks to expand indications for immunotherapy, recent data demonstrated that combining durvalumab with standard cytotoxic therapy improved survival in patients with ICC. This review focuses on the current and future strategies for ICC treatment, including a summary of the primary literature for each treatment modality and an algorithm that can be used to drive a personalized and multidisciplinary approach for patients with this challenging malignancy.  相似文献   
2.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
3.
4.
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号